tegafur has been researched along with Dermatitis Medicamentosa in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 9.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "The first case of Mucha-Habermann disease-like drug eruptions due to Tegafur is reported." | 7.70 | Mucha-Habermann disease-like eruptions due to Tegafur. ( Kawamura, K; Kuwabara, Y; Tsuji, T, 1999) |
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 5.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "The first case of Mucha-Habermann disease-like drug eruptions due to Tegafur is reported." | 3.70 | Mucha-Habermann disease-like eruptions due to Tegafur. ( Kawamura, K; Kuwabara, Y; Tsuji, T, 1999) |
| "Gemcitabine was administered at a dose of 1000 mg/m(2) over 30 min on days 1 and 8, and oral S-1 at a dose of 40 mg/m(2) twice daily from days 1 to 14, repeated every 3 weeks." | 2.76 | Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. ( Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O, 2011) |
| "Gemcitabine plus S-1 is a viable treatment alternative to gemcitabine, which is one of the standard treatments in patients with LAPC." | 1.46 | Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. ( Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T, 2017) |
| " on days 1-28, every 6 weeks) and assessed for all adverse events." | 1.35 | Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients. ( Fukushima, M; Ishiwata, R; Matsumoto, S; Nagai, Y; Teramukai, S; Yamanaka, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuda, K | 1 |
| Namiki, T | 1 |
| Ueno, M | 1 |
| Hashimoto, T | 1 |
| Hanafusa, T | 1 |
| Yokozeki, H | 1 |
| Hamada, C | 1 |
| Okusaka, T | 2 |
| Ikari, T | 1 |
| Isayama, H | 1 |
| Furuse, J | 2 |
| Ishii, H | 1 |
| Nakai, Y | 1 |
| Imai, S | 1 |
| Okamura, S | 1 |
| Park, YJ | 1 |
| Soh, BW | 1 |
| Lee, ES | 1 |
| Hsu, CH | 1 |
| Shen, YC | 1 |
| Lin, ZZ | 1 |
| Chen, PJ | 1 |
| Shao, YY | 1 |
| Ding, YH | 1 |
| Hsu, C | 1 |
| Cheng, AL | 1 |
| Ueno, H | 1 |
| Yamao, K | 1 |
| Funakoshi, A | 1 |
| Boku, N | 1 |
| Ohkawa, S | 1 |
| Yokosuka, O | 1 |
| Tanaka, K | 1 |
| Moriyasu, F | 1 |
| Nakamori, S | 1 |
| Sato, T | 1 |
| Arikawa, R | 1 |
| Kanekura, T | 1 |
| Uchimiya, H | 1 |
| Kanzaki, T | 1 |
| Yajima, T | 1 |
| Furukawa, Y | 1 |
| Ishii, Y | 1 |
| Hattori, Y | 1 |
| Matsumoto, N | 1 |
| Yamamoto, M | 1 |
| Yamaoka, Y | 1 |
| Fujihara, M | 1 |
| Fujita, M | 1 |
| Kuniki, H | 1 |
| Yamanaka, T | 1 |
| Matsumoto, S | 1 |
| Teramukai, S | 1 |
| Ishiwata, R | 1 |
| Nagai, Y | 1 |
| Fukushima, M | 1 |
| Jucglà, A | 1 |
| Sais, G | 1 |
| Navarro, M | 1 |
| Peyri, J | 1 |
| Kawamura, K | 1 |
| Tsuji, T | 1 |
| Kuwabara, Y | 1 |
| Revenga, F | 1 |
| Gelabert Mas, A | 1 |
| Arango Toro, O | 1 |
| Rosales Bordes, A | 1 |
| Coronado García, J | 1 |
| Fernández Zuazu, J | 1 |
2 trials available for tegafur and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesul | 2010 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ad | 2011 |
10 other studies available for tegafur and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Tegafur/gimeracil/oteracil (TS-1)-induced erythroderma with an extensive mucosal involvement and hand-foot syndrome.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neop | 2017 |
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2017 |
Acral lentiginosis associated with tegafur/gimeracil/oteracil (TS-1).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug C | 2017 |
A case of prurigo-type drug eruptions due to UFT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Drug Eruptions; Fe | 2003 |
[Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2 years].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cholestasis; Deoxycytidine; Drug Ad | 2004 |
Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cohort Studies; Drug Combin | 2008 |
Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur.
Topics: Adult; Drug Eruptions; Erythema; Female; Foot Dermatoses; Hand Dermatoses; Humans; Keratoderma, Palm | 1995 |
Mucha-Habermann disease-like eruptions due to Tegafur.
Topics: Antimetabolites, Antineoplastic; Drug Eruptions; Humans; Male; Middle Aged; Pityriasis Lichenoides; | 1999 |
Cutaneous side-effects caused by Tegafur.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Eruptions; Female; Humans; Hyperpigmentation; Male; Phot | 1999 |
[Oral cytostatic agents in the prevention of urothelial carcinoma. Our experience].
Topics: Administration, Oral; Adult; Aged; Carcinoma, Transitional Cell; Drug Eruptions; Foot Dermatoses; Ha | 1988 |